Allakos (ALLK)

• Market cap: $107M
• 1 day: -6.98%
• 5 days: 16.50%
• 1 month: 27.77%
• 3 months: 121.40%
• 6 months: 16.50%
• Year to date: -56.20%
• 1 year: -54.55%
• 5 years: -98.90%
• 10 years: -96.16%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

Employees: 131

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

3,000% more call options, than puts

Call options by funds: $31K | Put options by funds: $1K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

11.61% less ownership

Funds ownership: 90.68% [Q2] → 79.07% (-11.61%) [Q3]

23% less funds holding

Funds holding: 101 [Q2] → 78 (-23) [Q3]

43% less capital invested

Capital invested by funds: $80.3M [Q2] → $45.9M (-$34.4M) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 26

72% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 32

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 150% upside
• Avg. target: $3 150% upside
• High target: $3 150% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

JMP Securities Jonathan Wolleben 46% 1-year accuracy 34 / 74 met price target

150% upside $3

Market Outperform Reiterated

26 Sept 2024